Short answer
MIMEDX GROUP, INC. (MDXG) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). MiMedx to acquire Sanara for $33.00 cash plus 0.4735 MiMedx shares per Sanara share, implying $35.00 total stated consideration.
MIMEDX GROUP, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- MiMedx to acquire Sanara for $33.00 cash plus 0.4735 MiMedx shares per Sanara share, implying $35.00 total stated consideration
- $300.0 million first-lien senior secured term loan planned, increasing leverage and replacing MiMedx’s existing credit facility
- Sanara holders controlling approximately 38.9% of voting power committed to support the transaction
- Closing requires Sanara shareholder approval, antitrust clearance, effective Form S-4 registration, Nasdaq listing and other customary conditions
- Termination fees: $9,660,336 payable by Sanara in specified circumstances and $22,540,785 payable by MiMedx for failure to close as required
Item 7.01 · Regulation FD Disclosure
- MiMedx announced entry into a merger agreement on July 29, 2026, with Sanara MedTech
- Investor presentation expected to outline transaction timing, synergies, combined surgical revenue and Adjusted EBITDA margin
- Completion depends on Sanara stockholder approval, regulatory clearances and other closing conditions
- Proposed transaction introduces execution risks, including financing access, employee disruption and failure to realize synergies
- MiMedx plans an S-4 registration statement and Sanara proxy statement, key documents for valuation and shareholder voting decisions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MIMEDX GROUP, INC. 8-K filings
Get the next MDXG 8-K as it lands
Follow MDXG for push alerts, or ask the research agent what this filing means.